Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841560 | 0.85 | POLB (0.60) | ALDH1A1KDM4ETDP1GAATSHR | |
| SCHEMBL15682801 | 0.81 | KMT2A (0.55) | ALDH1A1TDP1MEN1KMT2APOLB | |
| SCHEMBL30831943 | 0.81 | HSD17B10 (0.75) | ALDH1A1KDM4ETDP1GAAMEN1 | |
| SCHEMBL1097902 | 0.81 | HSD17B10 (0.75) | ALDH1A1KDM4ETDP1GAAMEN1 | |
| SCHEMBL4032340 | 0.81 | NPC1 (0.66) | ALDH1A1TDP1 | |
| SCHEMBL6849659 | 0.81 | L3MBTL1 (0.58) | ALDH1A1KDM4ETDP1GAAMEN1 | |
| SCHEMBL3015241 | 0.80 | KMT2A (0.53) | ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL29576414 | 0.80 | KMT2A (0.53) | ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL24043968 | 0.80 | ALDH1A1 (0.61) | ALDH1A1KDM4ETDP1GAAMEN1 | |
| SCHEMBL11621845 | 0.80 | CTBP2 (0.63) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450777-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CHALCONE OR ITS DERIVATIVES FOR MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY | ANGIOLAB INC (KR) | 2013-05-08 | — | — | EP | disclosed |
| US-7572831-B2 | Composition containing chalcone | ANGIOLAB, INC. (KR) | 2009-08-11 | — | — | US | disclosed |
| US-20040209952-A1 | Composition containing chalcone | ANGIOLAB, INC. (KR) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209952-A1 | Composition containing chalcone | MMP25, MMP13, MMP17 | ALDH1A1 2424/4885KDM4E 1484/4885TDP1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.